Recent Updates
Recently added Catalysts
RDY Neutral Sentiment Score: 50/100

National Stock Exchange of India Ltd.

Key Takeaway: Dr Reddy's Laboratories is reportedly in discussions to acquire Nicotinell, an anti-smoking product, from its FTSE-100 parent. However, the company has stated that it does not comment on market speculations nor confirm any current event that mandates disclosure under SEBI regulations. The provided clarification highlights that no material information has been disclosed to the public regarding this potential acquisition.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr Reddy's Laboratories is exploring acquisition opportunities.
  • The company is engaged in discussions with a notable franchise.
  • The potential acquisition may enhance Dr Reddy's product offerings.

CONCERNS & RISKS

  • The company refrains from commenting on market speculations.
  • No material confirmation of the acquisition exists at this time.
  • Regulatory obligations limit disclosure regarding ongoing talks.

Full Press Release Details

National Stock Exchange of India Ltd. (Scrip Code:
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - information on reported
This is in reference
to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")
regarding a news item published in "Sky News" and available at the link: https://news.sky.com/story/indian-pharma-group-dr-reddys-eyes-swoop-on-nicotinell-13049500
on January 16, 2024, with the heading "Indian pharma group Dr Reddy's eyes swoop on Nicotinell".
The said news item is about "Dr Reddy's Laboratories,
an Indian pharmaceutical group, is in talks to buy Nicotinell, the anti-smoking aid, from its FTSE-100 parent company". In this
regard, please note that the Company does not comment on market speculations and there is currently no such event or information which
requires a disclosure under Regulation 30 of the SEBI Listing Regulations.
In compliance with Regulation 30 of the SEBI Listing
Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure
under the said Regulations.
This is for your information.
For Dr. Reddy's Laboratories Limited
/s/ K Randhir Singh
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR

Frequently Asked Questions

What is Dr Reddy's Laboratories in talks to acquire?

Dr Reddy's Laboratories is discussing the purchase of Nicotinell, an anti-smoking aid.

Which company owns Nicotinell?

Nicotinell is owned by a FTSE-100 parent company.

What is the company's stance on market speculation?

The company does not comment on market speculation regarding acquisitions.

Is there any required disclosure about this matter?

Currently, there's no information necessitating disclosure under SEBI regulations.

What regulations govern disclosures for the company?

Disclosures are governed by Regulation 30 of the SEBI Listing Regulations.

Last updated: Jan 16, 2024